Dosing Regimen of Aditoprim and Sulfamethoxazole Combination for the Glaesserella parasuis Containing Resistance and Virulence Genes

Anxiong Huang, Xiao Huang, Zhihao Zhang, Zonghui Yuan, Lingli Huang, Yulian Wang, Yanfei Tao, Dongmei Chen, Zhenli Liu, Haihong HaoPharmaceutics 2022 · DOI

TL;DR

This study addresses the challenge of treating Glasser's disease in pigs, caused by Glaesserella parasuis, which is increasingly resistant to antibiotics. By combining whole-genome sequencing with pharmacokinetics-pharmacodynamics (PK-PD) modeling, researchers determined an optimal dosing regimen of Aditoprim and Sulfamethoxazole (ADP/SMZ) to combat this pathogen. The findings offer a new therapeutic strategy to reduce the impact of this economically significant swine disease.

What Problem Does This Paper Address?

Glaesserella parasuis (G. parasuis) is a major bacterial pathogen responsible for Glasser's disease in pigs, leading to significant mortality, particularly in piglets. This disease manifests as fibrinous polyserositis, pleurisy, arthritis, and meningitis, causing substantial economic losses in the swine industry. A critical issue in treating G. parasuis infections is the growing problem of antibiotic resistance. Many commonly used antibiotics are becoming less effective, necessitating the development of new or combination therapies. Aditoprim (ADP) and Sulfamethoxazole (SMZ) are known to be effective against respiratory infections, and their combination is a promising avenue for treating G. parasuis, especially strains that carry resistance and virulence genes. However, determining the most effective way to administer this combination – the optimal dosing regimen – requires a deep understanding of how the drugs behave in the body and how they interact with the bacteria. This paper aims to fill that gap by establishing a PK-PD model to guide ADP/SMZ dosing for G. parasuis infections.

Methods

The study employed a multi-faceted approach:

  • Whole Genome Sequencing: The virulent G. parasuis strain H78 was sequenced to identify virulence-associated genes and drug resistance genes. This provides crucial context about the pathogen's characteristics.
  • In Vitro and Ex Vivo Pharmacodynamics (PD): Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) tests were performed to assess the antibacterial activity of ADP, SMZ, and their combination against G. parasuis isolates. Time-killing curves were generated to understand the kinetics of bacterial killing.
  • Pharmacokinetics (PK) Studies: The absorption, distribution, metabolism, and excretion of ADP and SMZ were studied in pigs. Blood plasma and pulmonary epithelial lining fluid (PELF) concentrations were measured over time after intramuscular injection.
  • PK-PD Modeling: The relationship between drug exposure (AUC/MIC) and antibacterial effect was modeled using a sigmoid Emax model. This integration of PK and PD data is key to predicting efficacy.
  • Dosing Regimen Optimization: Based on the PK-PD modeling and dose equations, an optimal dosing regimen was calculated for both healthy and infected pigs.

Datasets

  • G. parasuis Strains: 104 G. parasuis strains were used for antimicrobial susceptibility testing.
  • Virulent G. parasuis H78: This specific strain was selected for whole-genome sequencing and subsequent PK-PD studies due to its high virulence in mouse models.
  • Animal Models: Healthy and G. parasuis-infected pigs were used for PK studies. Healthy Balb/c mice were used for virulence screening.

Key Insights and Ideas

  • Genomic Basis of Virulence and Resistance: The whole-genome sequencing revealed that the virulent G. parasuis H78 strain harbors a significant number of genes associated with virulence and antibiotic resistance, underscoring the need for effective treatment strategies against such strains.
  • Synergistic Antibacterial Effect: The ADP/SMZ combination demonstrated a synergistic effect, with significantly improved antibacterial activity compared to either drug alone, particularly evident in the post-antimicrobial effect (PAE) studies.
  • Time-Dependent Antibacterial Activity: Both in vitro and ex vivo studies indicated that the antibacterial activity of ADP/SMZ against G. parasuis is time-dependent, suggesting that sustained drug exposure is crucial for efficacy. This led to the selection of AUC/MIC as the key PK-PD parameter.
  • Preferential Drug Accumulation in Lungs: PK studies showed that ADP and SMZ concentrations were higher in the pulmonary epithelial lining fluid (PELF) than in plasma, which is highly relevant for treating respiratory infections like Glasser's disease.
  • PK Similarity Between Healthy and Infected Pigs: Notably, there were no significant differences in the PK parameters of ADP and SMZ between healthy and infected pigs, simplifying the dosing strategy.

Key Results

  • Optimal Dosing Regimen: The study determined an optimal dosing regimen of 5/25 mg/kg b.w. of ADP/SMZ compound, administered intramuscularly once daily for 3-5 consecutive days for the treatment of G. parasuis infection.
  • MIC Values: The MIC of ADP/SMZ against G. parasuis H78 was found to be 2/10 µg/mL in vitro and 0.5/2.5 µg/mL ex vivo in PELF, indicating potent activity.
  • PK Parameters: The study provided detailed PK parameters (AUC, Tmax, T1/2λ, CL/F, Cmax) for ADP and SMZ in both plasma and PELF of pigs, which were essential for the PK-PD modeling. For instance, AUC24h in PELF was significantly higher than in plasma, reaching up to 166.16 µg/mL for SMZ.

Limitations and Future Work

  • Mouse Model for Virulence: While mice were used to screen for highly virulent strains, the primary PK studies were conducted in pigs. The direct translation of mouse virulence data to pig disease severity should be considered.
  • In Vivo Efficacy Confirmation: While the study provides a recommended dosing regimen based on PK-PD modeling, direct in vivo efficacy studies in experimentally infected pigs would further validate these findings.
  • Broader Strain Susceptibility: Although 104 strains were tested for MIC, the PK-PD modeling was primarily based on the virulent H78 strain. Further studies could explore if this regimen is effective against a wider range of G. parasuis serotypes and resistance profiles.
  • Long-Term Effects: The study focused on acute treatment. Future work could investigate the long-term impact of this regimen, including potential for resistance development over extended treatment periods.

The authors suggest that this study provides a theoretical basis for ADP/SMZ dose selection and contributes to controlling the prevalence and disease burden of G. parasuis, offering a novel therapeutic option for the veterinary field.

Summary updated

Abstract

<i>Glaesserella parasuis</i> (<i>G. parasuis</i>) causes Glasser's disease in pigs and causes high mortality in piglets. The new drug Aditoprim (ADP) alone or combined with Sulfamethoxazole (SMZ) is one of the good choices for treating respiratory infections. The objective of this study was to recommend the optimal dosing regimen for the treatment of <i>G. parasuis</i> infection which contains resistance and virulence genes by ADP/SMZ compound through pharmacokinetics-pharmacodynamics (PK-PD) modeling. The whole genome of the virulent strain <i>G. parasuis</i> H78 was obtained and annotated by whole genome sequencing. The results show that <i>G. parasuis</i> H78 consists of a unilateral circular chromosome with prophages in the genome. The annotation results of <i>G. parasuis</i> H78 showed that the genome contained a large number of virulence-related genes and drug resistance-related genes. The in vitro PD study showed that the antibacterial effect of ADP/SMZ compound against <i>G. parasuis</i> was time-dependent, and AUC/MIC was selected as the PK-PD modeling parameter. The PK study showed that the content of ADP/SMZ compound in pulmonary epithelial lining fluid (PELF) was higher than plasma, and there were no significant differences in ADP and SMZ PK parameters between the healthy and infected group. The dose equation to calculate the optimal dosing regimen of ADP/SMZ compound administration for control of <i>G. parasuis</i> infection was 5/25 mg/kg b.w., intramuscular injection once a day for 3~5 consecutive days. The results of this study provide novel therapeutic options for the treatment of <i>G. parasuis</i> infection to decrease the prevalence and disease burden caused by <i>G. parasuis</i>.
BibTeX
@inproceedings{huang2022dosing,
  author = {Anxiong Huang and Xiao Huang and Zhihao Zhang and Zonghui Yuan and Lingli Huang and Yulian Wang and Yanfei Tao and Dongmei Chen and Zhenli Liu and Haihong Hao},
  title = {{Dosing Regimen of Aditoprim and Sulfamethoxazole Combination for the Glaesserella parasuis Containing Resistance and Virulence Genes}},
  booktitle = {Pharmaceutics},
  year = {2022},
  doi = {10.3390/pharmaceutics14102058},
}
Figure